Australia · Delayed Price · Currency is AUD Control Bionics Company Description
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally.
The company offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices.
It also provides Cosmos Connect, a small portable control device that can be used with a Windows display device; NeuroNode, a wireless wearable sensor that gives the user the ability to access their technology by bioelectric signals or spatial movements; Uno Touch, a speech generating device; and NeuroNode Duo, a wireless sensor.
The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020.
Control Bionics Limited was incorporated in 2005 and is headquartered in Cremorne, Australia.
| Country | Australia |
| Founded | 2005 |
| Industry | Medical Devices |
| Sector | Healthcare |
| CEO | Jeremy Steele |
Contact Details
Address: 11-13 Pearson Street Cremorne, 3121 Australia | |
| Phone | 61 3 9897 3576 |
| Website | controlbionics.com |
Stock Details
| Ticker Symbol | CBL |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000114183 |
| SIC Code | 3842 |
Key Executives
| Name | Position |
|---|---|
| Jeremy E. Steele | Chief Executive Officer, MD and Director |
| Shannon Boothroyd | Chief Financial Officer |
| Todd Tyler | President of North America |
| James Schorey | Chief Technology Officer |
| Brett Thomas Crowley B.Com., BCom, C.A., CA, DipLaw | Company Secretary |